摘要
目的评估北京市1992-2013年乙型肝炎(乙肝)疫苗(Hepatitis B vaccine,HepB)接种预防乙肝肝硬化的效益-成本比(Benefit-cost ratio,BCR)。方法采用成本效益法测算1992-1993年北京市HepB接种成本、乙肝肝硬化花费和效益值,分析BCR。结果 1992-2013年北京市HepB免疫接种总成本为13 419.42万元,HepB接种为预防乙肝肝硬化带来的总效益为115 205.46万元,BCR为8.58。结论北京市HepB免疫接种对预防乙肝肝硬化具有较高的BCR。
Objective To estimate the benefit-cost ratio(BCR)of hepatitis B vaccine(HepB)vaccination for preventing hepatitis B related cirrhosis in Beijing during 1992-2013.Methods We used cost-benefit analysis to measure costs of HepB vaccination and expenses and benefits of preventing hepatitis B related cirrhosis to estimate a benefit-cost ratio(BCR).Results During 1992-2013,the total cost of HepB vaccination in Beijing was 134 194.2 thousand RMB.HepB vaccination produced a benefit of 1 152 054.6 thousand RMB in preventing hepatitis B related cirrhosis.The BCR of HepB vaccination was 8.58 for cirrhosis prevention.Conclusions HepB vaccination showed a high BCR in preventing hepatitis B related cirrhosis.
作者
白倩
袁淑婷
王溪
吴疆
石学峰
Bai Qian;Yuan Shuting;Wang Xi;Wu Jiang;Shi Xuefeng(School of Management,Beijing University of Chinese Medicine,Beijing 100029,China;Beijing Municipal Center for Disease Control and Prevention,Beijing 100013,China)
出处
《中国疫苗和免疫》
北大核心
2019年第2期121-125,共5页
Chinese Journal of Vaccines and Immunization
基金
北京市科学技术委员会课题项目(D161100002716005)
